Inventor · disambiguated record
Dale Kalamasz
Also filed as: KALAMASZ DALE
9 granted patents·14 pending applications·3,306 citations·filing 1995–2019
93Inventor score
Files withXCYTE THERAPIES INC12LIFE TECHNOLOGIES CORP4INVITROGEN CORP3BERENSON RONALD J1CARTER DARRICK1
Top patents by PatentIndex Score
23 records- 0197US7977095B2Generation and isolation of antigen-specific T cellsLIFE TECHNOLOGIES CORP·Filed 2008·Granted Jul 12, 2011·57 cites·14 claims
- 0297US6905874B2Simultaneous stimulation and concentration of cellsXCYTE THERAPIES INC·Filed 2001·Granted Jun 14, 2005·950 cites·43 claims
- 0397US6867041B2Simultaneous stimulation and concentration of cellsXCYTE THERAPIES INC·Filed 2002·Granted Mar 15, 2005·935 cites·21 claims
- 0497US6797514B2Simultaneous stimulation and concentration of cellsXCYTE THERAPIES INC·Filed 2001·Granted Sep 28, 2004·985 cites·14 claims
- 0596US9528088B2Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulationLIFE TECHNOLOGIES CORP·Filed 2013·Granted Dec 27, 2016·35 cites·6 claims
- 0696US7572631B2Activation and expansion of T cellsINVITROGEN CORP·Filed 2005·Granted Aug 11, 2009·217 cites·7 claims
- 0795US8617884B2Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulationBERENSON RONALD J·Filed 2008·Granted Dec 31, 2013·37 cites·6 claims
- 0879US7541184B2Activation and expansion of cellsINVITROGEN CORP·Filed 2004·Granted Jun 2, 2009·10 cites·2 claims
- 0968US5695989AApparatus and method for separating particles using a pliable vesselCELLPRO INC·Filed 1995·Granted Dec 9, 1997·80 cites·16 claims
- 1066US2020071663A1Methods for eliminating at least a substantial portion of a clonal antigen-specific memory t cell subpopulationLIFE TECHNOLOGIES CORP·Filed 2019·Application pending·0 cites
- 1162US2005153447A1Activation and expansion of cellsXCYTE THERAPIES INC·Filed 2004·Application pending·0 cites
- 1262US2005214942A1Activation and expansion of cellsXCYTE THERAPIES INC·Filed 2004·Application pending·0 cites
- 1359US2005084967A1Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantationXCYTE THERAPIES INC·Filed 2004·Application pending·0 cites
- 1458US2017114321A1Methods for eliminating at least a substantial portion of a clonal antigen-specific memory t cell subpopulationLIFE TECHNOLOGIES CORP·Filed 2016·Application pending·0 cites
- 1558US2007212767A1Generation and isolation of antigen-specific t cellsINVITROGEN CORP·Filed 2007·Application pending·0 cites
- 1656US2003119185A1Activation and expansion of cellsXCYTE THERAPIES INC·Filed 2002·Application pending·0 cites
- 1754US2004175373A1Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantationXCYTE THERAPIES INC·Filed 2003·Application pending·0 cites
- 1854US2004224402A1Generation and isolation of antigen-specific T cellsXCYTE THERAPIES INC·Filed 2003·Application pending·0 cites
- 1949US2003082806A1Maturation of antigen-presenting cells using activated T cellsXCYTE THERAPIES INC·Filed 2002·Application pending·0 cites
- 2048US2010069877A1Apparatus and method to dispense hpc-based viscous liquids into porous substrates, e.g., continuous web-based processSMITH GREGORY A·Filed 2009·Application pending·0 cites
- 2144US2004151704A1Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantationXCYTE THERAPIES INC·Filed 2003·Application pending·0 cites
- 2242US2003235908A1Activation and expansion of cellsXCYTE THERAPIES INC·Filed 2003·Application pending·0 cites
- 2339US2007083186A1Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehiclesCARTER DARRICK·Filed 2006·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →